Interactive Updates on Selected Topics in Gynecology Oncology - Cervix-Presentation Recording

Video Transcription

Video Summary

Summary 1 (Immunotherapy in Cervical Cancer):<br />The video discusses the current state of immunotherapy in cervical cancer. It explains that systemic therapy becomes the main treatment for metastatic, relapsed, or recurrent disease. The addition of bevacizumab to chemotherapy has shown an overall survival advantage. Immune checkpoints and disrupting the PD-1/PD-L1 axis can restore anti-tumor T-cell activity. Anti-PD-1 and anti-PD-L1 monoclonal antibodies have shown efficacy in various cancer types, including cervical cancer. The Keynote 158 trial with pembrolizumab showed promising results in patients who had progressed or were intolerant to first-line therapy. The disease control rate was 34.7%, and the overall response rate was 14.6%. Other trials, like GOG 3016 with dostarlamab, also showed promising efficacy. The speaker concludes that immunotherapy has shown promise in the treatment of cervical cancer, particularly in the recurrent or metastatic setting.<br /><br />Summary 2 (Treatment Options for Advanced Cervical Cancer):<br />The video discusses the treatment options for advanced cervical cancer. Concurrent chemoradiation therapy is the current standard of treatment. Surgery is generally not recommended as a first-line treatment due to complications. Adjuvant procedures like hysterectomy after radiation therapy may be considered in select cases. Salvage procedures, like pelvic exenteration, are used for recurrent or persistent disease. The role of surgery in isolated para-aortic lymph node metastasis is under investigation. Surgical staging helps determine the need for extended radiation fields. Surgical resection of lymph nodes after radiation therapy may be considered, but tumor leakage is a concern. Surgery may be used in regions with limited resources as a substitute for brachytherapy. However, the decision to perform surgery should consider feasibility and potential risks. Personalized treatment plans and further research in surgical options are highlighted.

Keywords

immunotherapy

cervical cancer

systemic therapy

metastatic

relapsed

recurrent disease

bevacizumab

chemotherapy

PD-1/PD-L1 axis

pembrolizumab

disease control rate

overall response rate

GOG 3016

dostarlamab

surgical options